A long-term Phase II/III study (IMT002) of an implantable telescope prosthesis for end-stage macular degeneration has demonstrated that it can improve quality of life and sustain visual acuity (VA) improvements.
A long-term Phase II/III study (IMT002) of an implantable telescope prosthesis for end-stage macular degeneration has demonstrated that it can improve quality of life and sustain visual acuity (VA) improvements, according to Mark Packer, one of the trial investigators from the USA.
The prospective, observational clinical trial enrolled 206 subjects across 28 US centres. Patients were over 55 years of age (mean age 76 years) with bilateral central scotomas due to untreatable age-related macular degeneration (AMD). Exclusion criteria included evidence or treatment of active choroidal neovascularization (CNV) in the preceding six months, diabetic retinopathy, history of retinal detachment, endothelial cell density <1,600 cells/mm2 and previous intraocular or corneal surgery.
Mean best corrected visual acuity (BCVA) at baseline was 20/312. At two years, mean BCVA had improved by 3.2 lines, within three letters of one year BCVA. A gain of more than three lines of distance BCVA was observed in 59.2% of implanted eyes, compared with 10.3% of fellow eye controls (p<0.0001).
The National Eye Institute Visual Function Questionnaire (NEI VFQ) scores, at one year, demonstrated relevant VFQ subscales improved from seven to 14 points. Mean endothelial cell density decreased by 20% at three months, 25.3% at one year and an additional 2.5% in year two. Two cases of corneal decompensation were recorded during year one, while none were seen in year two.
This pivotal study is the first to demonstrate that the implantable telescope can improve and sustain VA as well as improving quality of life.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.